Pharmanovia
Steve Deacon currently serves as Chief Scientific Officer at Pharmanovia since May 2022. Previously, Steve held the position of Chief Executive Officer and Chief Development Officer at Haoma Medica Ltd. from July 2019 to June 2022, and worked as a Drug Development Consultant on a freelance basis from December 2018 to June 2019. From August 2007 to November 2018, Steve was Senior Vice President and Head of EU/US Drug Development at ONO PHARMA, and prior roles included Vice President of Clinical Development (Europe) and Senior Director of Clinical Development. Earlier experience includes positions at LUNDBECK UK LLP, SmithKline Beecham, and a lecturer role in physiology and chemistry at the University of Surrey. Steve's academic background includes a PhD in Human Circadian Physiology & Behaviour from the University of Surrey and a Bachelor's degree in Applied Biological Sciences from the University of the West of England. Research interests focus on human circadian physiology and clinical research involving melatonin.
This person is not in any teams
Pharmanovia
2 followers
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by enhancing established medicines either by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and through strategic partnerships. Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.